Published in Circ Cardiovasc Qual Outcomes on November 18, 2013
Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol (2014) 1.00
APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrol Dial Transplant (2015) 0.84
High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan Study. Atherosclerosis (2014) 0.84
High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc (2015) 0.84
HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2015) 0.83
High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis (2016) 0.80
Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, controlled trial. Mol Nutr Food Res (2016) 0.78
Do all components of the metabolic syndrome cluster together in U.S. Hispanics/Latinos? Results from the Hispanic Community Health study/Study of Latinos. Ann Epidemiol (2015) 0.76
Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. Atherosclerosis (2015) 0.75
Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol (2017) 0.75
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med (2006) 4.91
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2001) 4.21
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res (2008) 3.71
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem (1995) 3.20
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol (2012) 3.11
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2007) 3.08
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA (2006) 2.99
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation (2012) 2.90
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol (2002) 2.38
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Ischemic heart disease, atherosclerosis, and longevity. Circulation (1966) 2.03
High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (2004) 2.00
HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation (1991) 1.94
Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol (2009) 1.83
Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med (2011) 1.75
The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol (2007) 1.70
Laboratory assessment of HDL heterogeneity and function. Clin Chem (2008) 1.67
Censoring issues in survival analysis. Annu Rev Public Health (1997) 1.40
Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis (2006) 1.35
High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb (1991) 1.34
Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol (1997) 1.30
A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol (2010) 1.22
Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med (2011) 1.20
High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol (2012) 1.19
Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol (2011) 1.09
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Curr Opin Lipidol (2013) 0.95
Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. J Lipid Res (2011) 0.82
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol (2012) 3.11
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation (2013) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation (2012) 2.17
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol (2011) 2.16
Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem (2007) 2.05
The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med (2007) 1.84
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Performance of reclassification statistics in comparing risk prediction models. Biom J (2011) 1.63
Clinical decisions. The guidelines battle on starting statins. N Engl J Med (2014) 1.58
Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care (2011) 1.44
Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. Eur Heart J (2013) 1.39
Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ (2011) 1.32
Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care (2008) 1.31
Novel locus including FGF21 is associated with dietary macronutrient intake. Hum Mol Genet (2013) 1.27
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med (2008) 1.21
Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study. PLoS One (2011) 1.21
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
The metabolic syndrome in women. Cardiol Rev (2006) 1.15
Exercise blood pressure and future cardiovascular death in asymptomatic individuals. Circulation (2010) 1.11
Discontinuation from HIV medical care: squandering treatment opportunities. J Health Care Poor Underserved (2003) 1.08
The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am Heart J (2010) 1.03
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J (2011) 1.00
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
Tests of calibration and goodness-of-fit in the survival setting. Stat Med (2015) 0.97
Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem (2012) 0.94
A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem (2013) 0.93
Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem (2011) 0.92
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol (2009) 0.88
Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol (2006) 0.88
Comments on 'Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers' by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg. Stat Med (2011) 0.86
Providing patients with global cardiovascular risk information: is knowledge power? Arch Intern Med (2010) 0.86
MSJAMA. The rural vs urban practice decision. JAMA (2002) 0.85
Fasting for lipid testing: Is it worth the trouble? Arch Intern Med (2012) 0.85
Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. Cardiol Rev (2006) 0.83
A national interactive web-based physical activity intervention in women, evaluation of the american heart association choose to move program 2006-2007. Am J Cardiol (2012) 0.83
Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". Arch Intern Med (2012) 0.81
A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord (2007) 0.80
Genetics and breast cancer risk prediction--are we there yet? J Natl Cancer Inst (2010) 0.79
Aspirin therapy in women: back to the ABCs. Circ Cardiovasc Qual Outcomes (2009) 0.76
Re.: "Association of small artery elasticity with incident cardiovascular disease in older adults: the Multi-ethnic Study of Atherosclerosis". Am J Epidemiol (2011) 0.76
Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. Metab Syndr Relat Disord (2010) 0.76
Are there sex differences in acute coronary syndrome presentation?: a guide through the maze. JAMA Intern Med (2013) 0.75
Biomarkers for prediction of cardiovascular events. N Engl J Med (2007) 0.75
What's different about women's health? Clin Chem (2014) 0.75
Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. Diabetes Res Clin Pract (2006) 0.75
Biphasic pulmonary regurgitation. Echocardiography (2009) 0.75
Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. Am J Epidemiol (2017) 0.75